BioNTech, Fosun start Phase II preliminary of COVID-19 vaccine in China Kumar Jeetendra | November 25, 2020 BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China. The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future acceptance in China, both firms …
China National Biotec Group Co. (CNBG), a leading vaccine developer has sought authorisation to bring its COVID-19 candidate to the current market Kumar Jeetendra | November 25, 2020 China National Biotec Group Co. (CNBG), a leading vaccine developer has sought authorisation to bring its COVID-19 candidate to the current market, Bloomberg has reported. The Bloomberg report cites Shi Shengyi, the vice general director of Sinopharm — CNBG’s parent company — as saying that an application in this regard was submitted to Chinese regulators …
Study uncovers a quality answerable for anthraquinone synthesis in plants Kumar Jeetendra | November 25, 2020 Anthraquinones are a class of naturally occurring chemicals prized for their medicinal properties, as well as for other programs, including ecologically friendly dyes. Despite broad interest, the mechanism by which plants produce them has remained shrouded in mystery until today. New work from an international group of scientists including Carnegie’s Sue Rhee shows a gene …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
Covaxin’s stage 3 preliminaries to begin in Sir JJ Hospital in Mumbai Kumar Jeetendra | November 26, 2020 The phase-3 clinical trials of India’s own COVID-19 vaccine candidate — Covaxin – will begin at Sir JJ Hospital in Mumbai. The medical facility is reportedly the second one in Maharashtra’s capital to start human trials of this vaccine candidate against the novel coronavirus following BMC-run Sion hospital. Covaxin has been developed by the Hyderabad-based …
Biocompatible photooxygenation catalyst could be conceivably used to treat amyloid infections Kumar Jeetendra | November 26, 2020 The catalyst was able to oxygenate Aβ embedded beneath the skin of a living mouse, and diminished intact Aβ degree in AD-model mouse brain. The new catalyst is potentially useful for the treatment of peripheral amyloid diseases and AD. Toxic aggregation of amyloid peptide and protein is closely associated with a number of human diseases. …
Researchers grow first plant-based gel to help organoid development for biomedical applications Kumar Jeetendra | November 26, 2020 Monash University researchers have created the world’s first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of research into cancer and COVID-19. This discovery by researchers in BioPRIA (Bioresource Processing Institute of Australia), Monash University’s Department of Chemical Engineering and the Monash Biomedicine Discovery Institute will develop organoids cheaper, …
Heparan Sulfate Products for COVID-19 Infection, Disease & Therapeutics Research Kumar Jeetendra | November 26, 2020 Heparan Sulfate (HS) is increasingly recognised as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the current COVID-19 Coronavirus pandemic. Using HS antibodies from AMSBIO, researchers have demonstrated that Heparanase enzyme contributes to the pathogenesis of COVID-19, with both Heparanase activity and HS levels being elevated in plasma of …
AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease Kumar Jeetendra | November 26, 2020 Specialist development pharmaceutical company AMZELL B.V has concluded discussions with the FDA ahead of initiating a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002. The Phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population. …
Eppendorf introduces refrigerated centrifuge Kumar Jeetendra | November 27, 2020 Eppendorf introduces the refrigerated 24-place centrifuge 5425 R, the successor of its popular centrifuge 5424 R. The new device comes with a bundle of improvements, making applications in the field of molecular and cell biology easier than ever. The superior cooling system not only protects temperature-sensitive samples of any kind even at full speed, it …
Novel method to detect single coronavirus particles Kumar Jeetendra | November 28, 2020 Scientists have developed a new method for identifying single virus particles based on changes in electrical current when they pass through ultrasmall pores, an advance which they claim may lead to new rapid COVID-19 tests. The study, published in the journal ACS Sensors, demonstrated a new system for identifying single virus particles using an algorithm …
The Thermo Scientific A45 Bath Circulators Enable Reliable Temperature Control Across the Most Demanding Applications Kumar Jeetendra | November 28, 2020 Life science, research and industrial laboratories undertaking temperature control applications can now minimize the environmental footprint of their operations with a new range of digitally-controlled bath circulators designed to enable significant water and energy savings, while using low global warming potential (GWP) hydrocarbon refrigerants. Offering superior performance, ease of use, and flexible, customizable cooling, heating …
